Approval of Additional Funding to Address the Health Crisis in Venezuela
Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;
Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;
Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/ER16 and Annex 1;
Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/ER16 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/ER16 and Annex 1;
Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV & TB health products for Venezuela and social monitoring of the investment; and
Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.
US$ 6,000,000, funded through available sources of funds identified by the Audit and Finance Committee under GF/AFC12/DP01.